182 related articles for article (PubMed ID: 37775689)
41. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
[TBL] [Abstract][Full Text] [Related]
42. Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.
Badaoui S; Kichenadasse G; Rowland A; Sorich MJ; Hopkins AM
Oncologist; 2021 Jul; 26(7):562-568. PubMed ID: 33914991
[TBL] [Abstract][Full Text] [Related]
43. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A; Raptis G; Baer LN; Oh SY; Zelnak AB; Wisinski KB; Andreopoulou E; Gradishar WJ; Stringer-Reasor E; Reid SA; O'Dea A; O'Regan R; Crew KD; Hershman DL
J Clin Oncol; 2023 Aug; 41(24):4004-4013. PubMed ID: 37207300
[TBL] [Abstract][Full Text] [Related]
44. The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
Giraudo A; Sabatier R; Rousseau F; De Nonneville A; Gonçalves A; Cecile M; Braticevic C; Viret F; Seguin L; Kfoury M; Naudet D; Hamon M; Tassy L
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791919
[TBL] [Abstract][Full Text] [Related]
45. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Rugo HS; Dieras V; Cortes J; Patt D; Wildiers H; O'Shaughnessy J; Zamora E; Yardley DA; Carter GC; Sheffield KM; Li L; Andre VAM; Li XI; Frenzel M; Huang YJ; Dickler MN; Tolaney SM
Breast Cancer Res Treat; 2020 Nov; 184(1):161-172. PubMed ID: 32789591
[TBL] [Abstract][Full Text] [Related]
46. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
47. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
[TBL] [Abstract][Full Text] [Related]
48. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
[TBL] [Abstract][Full Text] [Related]
49. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
[TBL] [Abstract][Full Text] [Related]
50. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Rugo HS; Huober J; García-Sáenz JA; Masuda N; Sohn JH; Andre VAM; Barriga S; Cox J; Goetz M
Oncologist; 2021 Jan; 26(1):e53-e65. PubMed ID: 32955138
[TBL] [Abstract][Full Text] [Related]
51. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.
Brufsky A; Liu X; Li B; McRoy L; Chen C; Layman RM; Rugo HS
Front Oncol; 2023; 13():1237751. PubMed ID: 37841423
[TBL] [Abstract][Full Text] [Related]
52. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
53. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
54. Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India.
Das Majumdar SK; Barik SK; Pattanaik A; Das DK; Parida DK
Cureus; 2024 Jan; 16(1):e52172. PubMed ID: 38344632
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
56. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
57. Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study.
Palumbo R; Torrisi R; Sottotetti F; Presti D; Rita Gambaro A; Collovà E; Ferzi A; Agostinetto E; Maria Teragni C; Saltalamacchia G; Tagliaferri B; Balletti E; Bernardo A; Quaquarini E
Ther Adv Med Oncol; 2021; 13():1758835920987651. PubMed ID: 33796150
[TBL] [Abstract][Full Text] [Related]
58. Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors.
Rottier P; Emile G; Johnson A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Dubot-Poitelon C; Boismoreau L; Cherifi F; Lequesne J; Da Silva A
Front Oncol; 2022; 12():1105587. PubMed ID: 36741710
[TBL] [Abstract][Full Text] [Related]
59. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.
Goyal RK; Chen H; Abughosh SM; Holmes HM; Candrilli SD; Johnson ML
Cancer; 2023 Apr; 129(7):1051-1063. PubMed ID: 36760031
[TBL] [Abstract][Full Text] [Related]
60. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
